Roundtable Discussion: Morgans Addresses How PSA Levels Affect Nonmetastatic CRPC Treatment
Summary of PSA Doubling Time and Velocity Definitions | Download Table
The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer
PSA Doubling Time Calculator
GitHub - conan-koh123/Calculating-PSA-Doubling-Time-for-many-patients: R code to calculate PSA doubling time (in months) for many patients
Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time | American Society of Clinical Oncology Educational Book
Cureus | Prognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature | Article
Prostate Cancer Nomograms: PSA Doubling Time | Memorial Sloan Kettering Cancer Center
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resista
The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
![Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging | EJNMMI Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13550-021-00869-5/MediaObjects/13550_2021_869_Fig1_HTML.png "Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging | EJNMMI Research | Full Text")
Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging | EJNMMI Research | Full Text
Oncology Resources - EOS | Emirates Oncology Society
A Commentary on PSA Velocity and Doubling Time for Clinical Decisions in Prostate Cancer
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure | SpringerLink
Low detectable PSA after prostatectomy – watch or treat? | THE "NEW" PROSTATE CANCER INFOLINK
PSA velocity and doubling time in diagnosis and prognosis of prostate cancer
PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section - Ali - 2007 - International
Month 134 – PSA Results | Dan's Journey through Prostate Cancer
El tiempo de doblaje de PSA como nuevo método diagnóstico y pronóstico del cáncer de próstata
Implications of Prostate-Specific Antigen Doubling Time as Indicator of Failure after Surgery or Radiation Therapy for Prostate
